Kim IA, et al. - In patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving EGFR-tyrosine kinase inhibitors (TKIs), researchers examined the impact of cumulative smoking dose (CSD) on clinical outcomes, including progression-free survival (PFS) and overall survival (OS) via retrospectively analyzing data of 142 patients with EGFR-mutation positive advanced or recurrent lung adenocarcinoma who were administered gefitinib, erlotinib, afatinib, and osimertinib. Statistically significant negative association was observed between CSD and median OS, and with median PFS in a statistically significant dose-dependent manner. The findings from the present study suggested that CSD was an important predictive and prognostic factor in patients with EGFR-mutated lung adenocarcinoma, and associated smoking-related gene signatures could affect the outcomes.